
Claims


1. A cell permeable iron chelating compound for use in the treatment of a solid cancer tumour, wherein the compound is a N-(1-pyridine-2-yl-methylidene)-N-(*9H*-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine of the formula I:



I

or a pharmaceutically acceptable salt or complex thereof.

2. Use of a cell permeable iron chelating compound in the manufacture of a medicament for the treatment of a solid cancer tumour, wherein the compound is a N-(1-pyridine-2-yl-methylidene)-N-(*9H*-1,3,4,9-tetraazafluoren-2-yl)-hydrazine of the general formula I:



I

wherein R is H or methyl, R^1 is H or C_1-C_4 alkyl, R^2 is H or C_1-C_4 alkyl; or a pharmaceutically acceptable salt or complex thereof.

3. The use according to claim 2, wherein R is methyl.

4. The use according to claim 2, wherein both of R, R^1 are methyl.

5. The use according to claim 2 or claim 3, wherein R^1 is methyl, in particular 6-methyl or 8-methyl.

6. The use according to claim 2, wherein R is methyl, R^1 is 8-methyl, and R^2 is H.

7. The use according to claim 2, wherein

R is	R^1 is	R^2 is	
Methyl	8-methyl	H;	or
Methyl	H	H;	or
Methyl	6-methyl	H;	or
H	6-methyl	H;	or,
H	8-methyl	CH_3.	

8. Use of a pharmaceutical composition comprising or consisting of the cell permeable iron chelating compound of claim 1 and a pharmaceutically suitable carrier in the manufacture of a medicament for the treatment of a solid cancer tumour.

9. The use according to claim 8, comprising a cancer combating effective dose of the cell permeable iron chelating compound.